Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection

Circulation Research

Volumn 78, Issue 5, 1996, Pages 769-779

  Worrall, Neil K ^a   Chang, Kathy ^a   Suau, Gloria M ^a   Allison, Wanda S ^a   Misko, Thomas P ^b   Sullivan, Patrick M ^b   Tilton, Ronald G ^a   Williamson, Joseph R ^a   Ferguson Jr , T Bruce ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONSANTO COMPANY   (United States)

^c Division of Cardiothoracic Surgery   (United States)

Author keywords

blood brain barrier; capillary permeability; cardiac transplantation; endothelium; nitric oxide

Indexed keywords

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; CAPILLARY PERMEABILITY; CELL INFILTRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INDUCTION; ENZYME INHIBITION; GRAFT REJECTION; HEART GRAFT; HEART TRANSPLANTATION; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE BLOOD FLOW;

EID: 0029921446     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.78.5.769     Document Type: Article

References (69)

1. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990;50:537-544.
2. Granger DN, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol. 1994;55:662-675.
3. Heemann UW, Tullius SG, Azuma H, Kupiec-Weglinsky J, Tilney NL. Adhesion molecules and transplantation. Ann Surg. 1994;219: 4-12.
4. Billingham ME. Diagnosis of cardiac rejection by endomyocardial biopsy. Heart Transplant. 1981;1:25-30.
5. Forbes RDC, Guttmann RD, Gomersall M, Hibberd J. A controlled serial ultrastructural tracer study of first-set cardiac allograft rejection in the rat. Am J Pathol. 1983;111:184-196.
6. Tilton RG, Chang K, Corbett JA, Misko TP, Currie MG, Bora NS, Kaplan HJ, Williamson JR. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci. 1994;35:3278-3288.
7. Boje KMK. Inhibition of nitric oxide synthase partially attenuates alterations in the blood-cerebrospinal fluid barrier during experimental meningitis in the rat. Eur J Pharmacol. 1995;272:297-300.
8. Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res. 1994;85:331-334.
9. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 1992;41:552-556.
10. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes. 1993;42:221-232.
11. Yuan Y, Granger HJ, Zawieja DC, Chilian WM. Flow modulates coronary venular permeability by a nitric oxide-related mechanism. Am J Physiol. 1992;263:H641-H646.
12. Boughton-Smith NK, Evans SM, Laszlo F, Whittle BJR, Moncada S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol. 1993;110: 1189-1195.
13. Lopez-Belmonte J, Whittle BJR. The involvement of endothelial dysfunction, nitric oxide and prostanoids in the rat gastric microcirculatory response to endothelin-1. Br J Pharmacol. 1994;112: 267-271.
14. Hughes SR, Williams TJ, Brain SD. Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. Eur J Pharmacol. 1990;191:481-484.
15. Ialenti A, Ianaro A, Moncada S, Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol. 1992; 211:177-182.
16. 4-induced increases in microvascular transport. Am J Physiol. 1993;265: H409-H414.
17. Yuan Y, Granger HJ, Zawieja DC, DeFily DV, Chilian WM. Histamine increases venular permeability via a phospholipase C-NO synthase-guanylate cyclase cascade. Am J Physiol. 1993;264: H1734-H1739.
18. Mayhan WG. Nitric oxide accounts for histamine-induced increases in macromolecular extravasation. Am J Physiol. 1994;266: H2369-H2373.
19. Mayhan WG. Role of nitric oxide in modulating permeability of hamster cheek pouch in response to adenosine 5′-diphosphate and bradykinin. Inflammation. 1992;16:295-305.
20. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43: 109-142.
21. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-3064.
22. Yang X, Chowdhury N, Cai B, Brett J, Marboe C, Sciacca RR, Michler RE, Cannon PJ. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest. 1994;94: 714-721.
23. Worrall NK, Lazenby WD, Misko TP, Lin T-S, Rodi CP, Manning PT, Tilton RG, Williamson JR, Ferguson TB Jr. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med. 1995;181:63-70.
24. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, Currie MG. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol. 1993;233:119-125.
25. Griffiths MJD, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol. 1993;110:963-968.
26. Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys. 1995;316:290-301.
27. Wu CJ, Lovett M, Wong-Lee J, Moeller F, Kitamura M, Goralski TJ, Billingham ME, Starnes VA, Clayberger C. Cytokine gene expression in rejecting cardiac allografts. Transplantation. 1992;54: 326-332.
28. Maury CPJ, Teppo A-M. Raised levels of cachectin/tumor necrosis factor α in renal allograft rejection. J Exp Med. 1987;166:1132-1137.
29. Imagawa DK, Millis JM, Olthoff KM, Derus LJ, Chia D, Sugich LR, Ozawa M, Dempsey RA, Iwaki Y, Levy PJ, Terasaki PI, Busuttil RW. The role of tumor necrosis factor in allograft rejection, I: evidence that elevated levels of tumor necrosis factor-α predict rejection following orthotopic liver transplantation. Transplantation. 1990;50:219-225.
30. Slivka A, Chuttani R, Carr-Locke DL, Kobzik L, Bredt DS, Loscalzo J, Stamler JS. Inhibition of sphincter of Oddi function by the nitric oxide carrier S-nitroso-N-acetylcysteine in rabbits and humans. J Clin Invest. 1994;94:1792-1798.
31. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A. 1992;89:7674-7677.
32. Keaney JF, Simon DI, Stamler JS, Jaraki O, Scharfstein J, Vita JA, Loscalzo J. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest. 1993;91:1582-1589.
33. Scharfstein JS, Keaney JF Jr, Slivka A, Welch GN, Vita JA, Stamler JS, Loscalzo J. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest. 1994;94:1432-1439.
34. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg. 1969;57:225-229.
35. Pugliese G, Tilton RG, Chang K, Speedy A, Province M, Eades DM, Lacy PE, Kilo C, Williamson JR. Effects of islet isografts on hemodynamic and vascular filtration changes in diabetic rats. Diabetes. 1990;39:323-332.
36. Pugliese G, Tilton RG, Speedy A, Santarelli E, Eades DM, Province MA, Kilo C, Sherman WR, Williamson JR. Modulation of hemodynamic and vascular filtration changes in diabetic rats by dietary myo-inositol. Diabetes. 1990;39:312-322.
37. Haraldsson B, Regner L, Hultborn R, Weiss L, Rippe B. Transcapillary passage of albumin in mammary tumours and in normal lactating mammary glands of the rat. Acta Physiol Scand. 1984;122: 497-505.
38. Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR, Kilo C, Williamson JR. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes. 1989;38:1258-1270.
39. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem. 1993;214:11-16.
40. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
41. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest. 1994;93:2684-2690.
42. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232:1629-1632.
43. Hui JY, Taylor SL. Inhibition of in vivo histamine metabolism in rats by foodborne and pharmacologic inhibitors of diamine oxidase, histamine N-methyltransferase, and monoamine oxidase. Toxicol Appl Pharmacol. 1985;81:241-249.
44. Kumari K, Umar S, Bansal V, Sahib MK. Inhibition of diabetes-associated complications by nucleophilic compounds. Diabetes. 1991;40:1079-1084.
45. Kilzer P, Chang K, Marvel J, Kilo C, Williamson JR. Tissue differences in vascular permeability changes induced by histamine. Microvasc Res. 1985;30:270-285.
46. Palmer RMJ, Bridge L, Foxwell NA, Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol. 1992;105:11-12.
47. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A. 1993;90:7240-7244.
48. Corbett JA, Kwon G, Turk J, McDaniel ML. IL-1 beta induces co-expression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry. 1993;32:13767-13770.
49. Russell ME, Wallace AF, Wyner LR, Newell JB, Karnovsky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation. 1995;92:457-464.
50. Worrall N, Chang K, Misko T, Allison W, Williamson JR, Ferguson TB Jr. Tumor necrosis factor (TNF) causes systemic endothelial dysfunction. FASEB J. 1995;9:A960. Abstract.
51. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol. 1986;137:1735-1742.
52. Ignarro LJ, Lippton H, Edwards JC. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981;218:739-749.
53. Myers PR, Minor RL, Guerra R, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature. 1990; 345:161-163.
54. Lancaster JR Jr, Langrehr JM, Bergonia HA, Murase N, Simmons RL, Hoffman RA. EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. J Biol Chem. 1992;267:10994-10998.
55. 2 in the rat. Prostaglandins. 1986;32:5-17.
56. Williamson JR, Holmberg SW, Chang K, Marvel J, Sutera SP, Needleman P. Mechanisms underlying atriopeptin-induced increases in hematocrit and vascular permeation in rats. Circ Res. 1989;64:890-899.
57. Ramilo O, Sáez-Llorens X, Mertsola J, Jafari H, Olsen KD, Hansen EJ, Yoshinaga M, Ohkawara S, Nariuchi H, McCracken GH Jr. Tumor necrosis factor α/cachectin and interleukin-1β initiate meningeal inflammation. J Exp Med. 1990;172:497-507.
58. Quagliarello VJ, Wispelwey B, Long WJ Jr, Scheid WM. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat: characterization and comparison with tumor necrosis factor. J Clin Invest. 1991;87:1360-1366.
59. Anwar M, Costa O, Sinha AK, Weiss HR. Middle cerebral artery occlusion increases cerebral capillary permeability. Neurol Res. 1993;15:232-236.
60. Long JB, Holaday JW. Blood-brain barrier: endogenous modulation by adrenal-cortical function. Science. 1985;227:1580-1583.
61. Marsault R, Frelin C. The activation by nitric oxide of guanylate cyclase in endothelial cells from brain capillaries. J Neurochem. 1992;59:942-945.
62. Joe F, Temesvári P, Dux E. Regulation of the macromolecular transport in the brain microvessels: the role of cyclic GMP. Brain Res. 1983;278:165-174.
63. Chi OZ, Wei HM, Sinha AK, Weiss HR. Effects of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia. Pharmacology. 1994;48:367-373.
64. Oliver JA. Endothelium-derived relaxing factor contributes to the regulation of endothelial permeability. J Cell Physiol. 1992;151: 506-511.
65. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol. 1992;262:H611-H615.
66. Kurose I, Kubes P, Wolf R, Anderson DC, Paulson J, Miyasaka M, Granger DN. Inhibition of nitric oxide production: mechanisms of vascular albumin leakage. Circ Res. 1993;73:164-171.
67. Filep JG, Földes-Filep E, Sirois P. Nitric oxide modulates vascular permeability in the rat coronary circulation. Br J Pharmacol. 1993; 108:323-326.
68. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991; 88:4651-4655.
69. Suematsu M, Tamatani T, Delano FA, Miyasaka M, Forrest M, Suzuki H, Schmid-Schönbein GW. Microvascular oxidative stress preceding leukocyte activation elicited by in vivo nitric oxide suppression. Am J Physiol. 1994;266:H2410-H2415.